The global anti-tumor drugs market size is projected to register a substantial CAGR during the forecast period, 2021-2028 attributed to upcoming patents, continuous development going on in the medicinal field, and its increasing demand. Moreover, increase in the incidence of cancer cases globally is also expected to boost market growth.
The abnormal proliferation of tissues cause tumors. Genetic mutations can be a cause of abnormal proliferation of tissues. A type of drug that is used to block the growth of cancer cells by interfering with DNA is known as the anti-tumor drugs. These drugs are also widely known as anticancer drugs. Reports by the World Health Organization (WHO) state that the number of cancer cases is expected to reach 15 million by 2025. Similarly, a fact sheet by the Globocan 2020 stated that nearly 19,292,789 new cancer cases were diagnosed globally and around 9,958,133 deaths took place due to cancer.
The COVID-19 pandemic outbreak had a negative impact on the global anti-tumor drugs market attributed to sudden shift of focus of pharmaceutical and medical institutions on preventing the widespread of the COVID infection. The article published in the Cancer Connect 2020 suggested that the diagnosis of the most common cancers including blood cancer, lung cancer, breast cancer, and others had been decreased by 46% during the early phase of the pandemic. The screening of the cancer is also sparsely done as many hospitals utilize their infrastructures for the treatment of patients infected with COVID-19. However, it is anticipated that the situation will improve gradually in the post-COVID situation.
The report on the global anti-tumor drugs market includes an assessment of the market, trends, and segments. Overview and dynamics have also been included in the report.
Attributes |
Details |
Report Title |
Anti-tumor Drugs Market – Global Industry Analysis, Growth, Share, Size, Trends, And Forecast |
Base Year |
2020 |
Historic Data |
2018–2019 |
Forecast Period |
2021–2028 |
Segmentation |
Types (Blood Cancer, Lung Cancer, Breast Cancer, and Others) and Applications (Chemotherapy, Targeted Therapy [Monoclonal Antibody and Small Molecule Drugs], Surgical, Radiation, and Immunotherapy) |
Regional Scope |
Asia Pacific, North America, Latin America, Europe, and Middle East & Africa |
Report Coverage |
Company Share, Market Analysis and Size, Competitive Landscape, Growth Factors, and Trends, and Revenue Forecast |
Key Players Covered in the Report |
Roche; Celgene; and Novartis |
On the basis of types, the global anti-tumor drugs market is divided into blood cancer, lung cancer, breast cancer, and others. The blood cancer segment is anticipated to hold a large share of the market during the forecast period attributed to the high cost of therapies and wide prevalence of the type of cancer worldwide.
Based on applications, the market is segmented into chemotherapy, targeted therapy, surgical, radiation, and immunotherapy. The targeted therapy segment is further bifurcated into monoclonal antibody and small molecule drugs. The targeted therapy segment is expected to hold a significant share during the forecast period of the market attributed to increasing in research & development.
Targeted therapy are drugs that are engineered especially that act only in the targeted regions without causing little to no harm to the surrounding area. Several research and technological innovations are taking place in the field of biotechnology in order to increase the availability and effectiveness of monoclonal antibody drugs. Monoclonal antibody drugs include panitumumab and rituximab while drugs such as imatinib is used for immunotherapy that helps to stimulate the immune system of an individual against cancer cells. The immunotherapy segment is expected to boost at an impressive growth rate during the projected period.
In terms of regions, the global anti-tumor drugs market is classified as Asia Pacific, North America, Latin America, Europe, and Middle East & Africa. North America is expected to hold a major share of the market in the coming years owing to wide number of cancer patients and high adoption of drugs among a large number of the targeted population in the region. However, the market of Asia Pacific is estimated to expand at a substantial rate in the coming years attributed to lack of availability of drugs and high mortality due to cancer in the region.
The global anti-tumor drugs market has been segmented on the basis of
Key players competing in the global anti-tumor drugs market are Roche; Celgene; and Novartis. Many of these players have adopted business strategies such as the launch of new products, the advancement of technologies, partnerships, mergers, and production capacity expansion in order to increase their consumer base and expand their market position globally. For instance, the oncology unit of GlaxoSmithKline was acquired by Novartis to expand the development of innovative cancer treatment drugs.
Some other reports from this category!